Lyme arthritis in Western Europe: a multicentre retrospective study

To characterize Lyme arthritis, with a focus on management, and outcome. Observational retrospective multicentre study in Western France, of all consecutive cases of Lyme arthritis, documented by Borrelia burgdorferi IgG on ELISA serological testing, confirmed by Western blot, with or without positive Borrelia PCR in synovial fluid, with no alternative diagnosis. We enrolled 52 patients (29 males), with a mean age of 43 ± 19.4 years. Most patients had monoarthritis ( n = 43, 82.7%), involving the knee ( n = 51, 98.1%), with a median delay between symptoms onset and Lyme arthritis diagnosis of 5 months (interquartile range, 1.5–8). Synovial fluid analysis yielded median white cell count of 16,000/mm 3 (9230–40,500), and positive PCR in 16 cases (39%), for B. burgdorferi sensu stricto ( n = 5), B. garinii ( n = 5), B. afzelii ( n = 3), and undetermined ( n = 3). All patients received antibiotics, for a median duration of 28 days (21–30), with doxycycline ( n = 44, 84.6%), ceftriaxone ( n = 6, 11.5%), or amoxicillin ( n = 2). Twelve patients (23.1%) also received intra-articular injection of glucocorticoids as first-line treatment. Of 47 patients with follow-up, 35 (74.5%) had complete resolution of Lyme arthritis. Lyme arthritis in Western Europe may be due to B. burgdorferi ss , B. afzelii , or B. garinii . Clinical presentation is similar to Lyme arthritis in North America (i.e. chronic knee monoarthritis), with low sensitivity of synovial fluid PCR (39%).